Related Experiment Video

Updated: Mar 1, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

26.9K

Implantable Cardioverter Defibrillator for the Primary Prevention of Sudden Cardiac Death in Patients With

Rafael Cavalcanti1, Nael Aboul-Hosn1, Gustavo Morales1

  • 11 Department of Cardiology, Gill Heart Institute, University of Kentucky, Lexington, KY, USA.

Angiology
|May 31, 2017
PubMed

Insights

Implantable cardioverter defibrillators (ICDs) significantly reduce mortality in nonischemic cardiomyopathy patients. This meta-analysis confirms ICDs provide a 21% relative risk reduction for sudden cardiac death prevention in this population.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Interventions

Background:

  • Nonischemic cardiomyopathy (NICMP) poses a risk for sudden cardiac death.
  • The primary prevention benefit of implantable cardioverter defibrillators (ICDs) in NICMP is not well-established by randomized controlled trials.
  • Recent studies have also yielded inconclusive results regarding ICD efficacy in NICMP.

Purpose of the Study:

  • To systematically review and meta-analyze the effectiveness of ICDs for primary prevention of mortality in patients with NICMP.
  • To determine if ICD implantation reduces all-cause mortality in the NICMP population.
  • To provide evidence-based guidance on ICD use for primary prevention in NICMP.

Main Methods:

  • Systematic literature search for randomized controlled trials (RCTs) on ICDs in NICMP.
  • Primary outcome: all-cause mortality.
  • Fixed-effects model used for meta-analysis.

Main Results:

  • Five RCTs met inclusion criteria, individually showing inconsistent benefits of ICDs in NICMP.
  • Pooled analysis of these trials demonstrated a 21% relative risk reduction in mortality with ICD implantation (RR: 0.79; 95% CI: 0.66-0.95).
  • This suggests a significant survival benefit in the studied population.

Conclusions:

  • Implantable cardioverter defibrillators (ICDs) are associated with decreased mortality for primary prevention in nonischemic cardiomyopathy patients.
  • The benefit is particularly noted in patients with a left ventricular ejection fraction below 35%.
  • This meta-analysis supports the use of ICDs for primary prevention in select NICMP patients.
Abstract

Keywords:
ICDNICMPimplantable cardioverter defibrillatornonischemic cardiomyopathyprimary preventionsudden cardiac death

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.0K
Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.3K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
675
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
578
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
773
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
704
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
545